Report overview
The global VMAT2 Inhibitors market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Tetrabenazine Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of VMAT2 Inhibitors include Neurocrine Biosciences, Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals plc, Hetero, Bausch Health Companies Inc, Dr. Reddy's Laboratories Ltd, Piramal Pharma Solution and Lupin, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Vesicular monoamine transporter-2 is the transmembrane protein which is primarily responsible for the transport of monoamines neurotransmitters such as histamines, serotonin, dopamine, and norepinephrine into the synaptic vesicles. VMAT2 transporter carries the cytoplasmic dopamine into the vesicles. VMAT2 inhibitors reduce the dopamine at the presynaptic striatal nerve terminals and decrease unwanted body movements for these conditions. VMAT2 inhibitors are widely used to treat uncontrollable involuntary, repetitive body movements caused by tardive dyskinesia and Huntington?s disease.
This report aims to provide a comprehensive presentation of the global market for VMAT2 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VMAT2 Inhibitors. This report contains market size and forecasts of VMAT2 Inhibitors in global, including the following market information:
Global VMAT2 Inhibitors Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global VMAT2 Inhibitors Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five VMAT2 Inhibitors companies in 2023 (%)
We surveyed the VMAT2 Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global VMAT2 Inhibitors Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global VMAT2 Inhibitors Market Segment Percentages, by Type, 2023 (%)
Tetrabenazine
Valbenazine
Other
Global VMAT2 Inhibitors Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global VMAT2 Inhibitors Market Segment Percentages, by Application, 2023 (%)
Huntington?s Disease
Tardive Dyskinesia
Other
Global VMAT2 Inhibitors Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global VMAT2 Inhibitors Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies VMAT2 Inhibitors revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies VMAT2 Inhibitors revenues share in global market, 2023 (%)
Key companies VMAT2 Inhibitors sales in global market, 2019-2024 (Estimated), (K Units)
Key companies VMAT2 Inhibitors sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Neurocrine Biosciences, Inc
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Hikma Pharmaceuticals plc
Hetero
Bausch Health Companies Inc
Dr. Reddy's Laboratories Ltd
Piramal Pharma Solution
Lupin
Luye Pharma Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of VMAT2 Inhibitors, market overview.
Chapter 2: Global VMAT2 Inhibitors market size in revenue and volume.
Chapter 3: Detailed analysis of VMAT2 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of VMAT2 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global VMAT2 Inhibitors capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
